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Abstract 
Review on TGFBR2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: AAT3, FAA3, LDS1B, LDS2B, 
MFS2, RIIC, TAAD2, TGFR-2, TGFbeta-RII 
HGNC (Hugo): TGFBR2 
Location: 3p24.1 
Note 
Ensembl version: ENSG00000163513  
SwissProt ID: P37173 
ENZYME entry: EC=2.7.11.30 
DNA/RNA 
Description 
Length of TGFBR2 gene is 87641 bases. TGFBR2 
gene encodes 8 exons. Orientation: plus strand. 
Transcription 
The TGFBR2 gene encodes two well-known 
protein coding transcripts:  
- TGFBR2-001 (Ensembl version 
ENST00000295754.5): Encoded by 7 exons; 
mRNA length: 4621 bps; Translation length: 567 
amino acid residues;  
- TGFBR2-002 (Ensembl version 
ENST00000359013.4): Encoded by 8 exons; 
mRNA length: 4605 bps; Translation length: 592 
amino acid residues.  
Protein 
Description 
The TGFBR2 gene encodes two proteins through 
alternative splicing (592 aa and 567 aa long 
respectively); both can convey TGFβ signals. 
TGFBR2 is a transmembrane Serine/Threonine 
kinase. It has a molecular weight of 70/80kD. 
TGFBR2 consist of an N-terminal extra-cellular 
ligand binding ectodomain, a transmembrane 
region, and a C-terminal serine/threonine kinase 
domain. The ectodomain is formed by nine beta-
strands and a single helix stabilised by a network of 
six intra strand disulphide bonds (Hart et al., 2002). 
Expression 
This protein is ubiquitously expressed in all cell 
types. Loss of TGFBR2 expression is linked with 
many pathological conditions involving cancer. The 
level of expression may vary depending up on cell-
type. 
Localisation 
Primarily, it is a transmembrane protein, involved 
in extra-cellular TGFβ ligand binding. However, 
ligand binding can trigger internalization of both 
ligand and receptors. Receptors internalized in 
endosomes can either be targeted to lysosomes for 
degradation or be recycled back to the cell surface 
for re-use (Chen et al., 2009). 
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Structure and the mechanism of TGFBR2 activation: The TGFBR2 consists of an N-terminal extra-cellular ligand binding 
domain, a transmembrane region, and a cytoplasmic, C-terminal serine/threonine kinase domain. On TGFβ ligand mediated 
activation, TGFBR2 forms hetero tetramers with TGFBR1 and triggers TGFBR1 kinase activity by phosphorylating the GS 
domain. The activated TGFBR1 kinase can phosphorylate downstream SMAD transcription factors and there by mediate the 
expression of TGFβ-responsive genes. 
 
 
Function 
TGFBR2 is an important member of the 
Transforming Growth Factor Beta (TGFβ) 
signaling pathway. The TGFβ signaling controls 
important cellular activities like cytostasis, 
apoptosis, epithelial to mesenchymal transition 
(EMT), migration, etc. in a context dependent 
manner (Massague et al., 2005; Feng and Derynck, 
2005). These pleiotropic cytokines are encoded by 
42 open reading frames in human. They are divided 
into two subfamilies, the TGFβ/Activin/Nodal 
subfamily and the BMP(bone morphogenetic 
protein)/GDF(growth and differentiation 
factor)/MIS(Muellerian inhibiting substance) 
subfamily, as defined by sequence similarity and 
the specific signaling pathways that they activate 
(Shi and Massague, 2003). These cytokines are 
known to convey cellular signals through the 
serine/threonine kinase family receptors - 7 type I 
and 5 type II receptors - that are dedicated to TGFβ 
signaling (Manning et al., 2002). TGFBR2 is the 
most important and well-characterized type II 
receptor of TGFβ family. 
The TGFβ-SMAD signaling cascade gets activated 
when TGFβ ligand binds to the TGFBR2 
(Massague, 1998; Shi and Massague, 2003). The 
TGFβ ligand is secreted as latent complex in which 
the TGFβ dimer is bound to the latency-associated 
peptide (LAP) (Young and Murphy-Ullrich, 2004). 
Many latent TGFβ binding proteins (LTBPs) can  
bind to and sequester this latent complex to extra 
cellular matrix (ECM) (Derynck et al., 2001). The 
latent TGFβ is activated by plasmins and MMP2 
and MMP9 through proteolytic processing that 
leads to removal of LAP. The active form of TGF-β 
is a 25 KDa disulphide linked homodimer. 
(Derynck et al., 2001; Padua and Massague, 2009). 
TGFBR2 is a constitutively active kinase that 
occurs as homodimer (Hart et al., 2002; Shi and 
Massague, 2003). On ligand binding mediated 
activation, TGFBR2 forms heteromeric complex 
with type I TGFβ receptor (TGFBR1) (Luo and 
Lodish, 1997).  
TGFBR2 kinase mediated phosphorylation of 
Glycine/Serine-rich GS domain of TGFBR1 leads 
to activation of type I receptor kinase. Activated 
TGFBR1 then phosphorylates downstream SMAD 
transcription factors. 
The pathway restricted SMADs-SMAD2 and 
SMAD3- are involved in signaling through 
TGFBR2/TGFBR1 receptor complexes. They are 
commonly called receptor regulated SMADs or R-
SMADs. They bind directly to TGFBR1 and are 
phosphorylated at a C-terminal SSXS motif, that is 
exclusive and conserved for R-SMADs (Feng and 
Derynck, 2005; Schmierer and Hill, 2007). SMAD4 
lacks a C-terminal SSXS motif and does not 
interact directly with TGFBR1. SMAD4 is 
commonly referred to as co-SMAD and serves as a 
common partner for all R-SMADs (Shi and 
Massague, 2003). 
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The binding of the R-SMAD to the type I receptor 
is mediated by adaptor proteins like SARA (SMAD 
anchor for receptor activation), a zinc double finger 
FYVE domain containing protein.  
They restrict SMAD2/3 proteins to the plasma 
membrane and early endosomes and thus facilitate 
the interaction of SMAD2/3 proteins with activated 
TGFBR1 (Panopoulou et al., 2002; Chen, 2009). 
The phosphorylated R-SMADs can form 
heteromeric complex with the common mediator 
SMAD (Co-SMAD, SMAD4) and this enables the 
nuclear translocation of the complex (Wrighton et 
al., 2009).  
In the nucleus, the SMAD transcription factors 
orchestrate the expression of various target genes; 
depending on the DNA binding partners they 
associate (Massague, 2008).  
The DNA binding partners are responsible for the 
context dependency exhibited by TGFβ signaling 
(Inman, 2005). Many protein phosphatases are 
responsible for switching off TGFβ signaling 
through R-SMAD dephosphorylation and dictate 
the strength and duration of TGFβ signaling 
(Wrighton et al., 2009).  
The inhibitory SMADs (SMAD 6 and SMAD 7) are 
responsible for feedback repression of this signaling 
pathway (Xu, 2006). SMAD7 acts through 
competition for receptor mediated phosphorylation, 
and through the recruitment of SMAD 
ubiquitination regulatory Factors1 or 2 
(Smurf1/Smurf2) to R- SMADs (Lönn et al., 2009). 
In addition to the canonical signaling through the 
SMADs, TGFBR2 can activate many non-SMAD 
pathways like PI3K-Akt, JNK, p38MAPK, ROCK, 
PKC, PP2A, Ras, Erk1/Erk2 and Rho-like GTPases 
including RhoA, Rac and Cdc42 (Zhang, 2009). 
These non-SMAD signaling pathways add greatly 
towards the context-dependent nature of TGFβ 
signaling. 
Many studies consider TGFβ alterations as a key 
reason for tumorigenesis (Derynck et al., 2001; 
Seoane, 2006).  
These alterations arise at genetic as well as at 
epigenetic level.  
While mutations are responsible for major share of 
genomic level TGFβ aberrations, the microRNA 
alterations contribute towards a fair share of the 
epigenetic alterations (Sivadas and Kannan, 2013). 
Besides, loss of integration of TGFβ signaling with 
other important pathways such as p53 signaling is 
an important reason for tumorigenesis (Massague, 
2008). 
Homology 
The TGFBR2 gene is conserved in human, 
chimpanzee, Rhesus monkey, dog, cow, mouse, rat, 
chicken and zebra fish. Notably, TGFBR2 of 
human beings and chimpanzee shows 100% and 
99.6% identity, at protein and DNA level 
respectively. Furthermore, 72 organisms have 
orthologs with human gene TGFBR2. 
Mutations 
Note 
Somatic mutations of TGFBR2 is a common event 
in various cancers (Seoane, 2006), Loeys-Dietz 
syndrome, Marfan syndrome, etc. (Loeys et al., 
2006; Singh et al., 2006; Stheneur et al., 2008). 
Deletion of the chromosomal region 3p, that carries 
TGFBR2 is reported in many solid tumors (Kok et 
al., 1997). 
Implicated in 
Lung cancer 
Disease 
Lung cancer is the leading cancer in terms of 
incidence and death world-wide.  
The most important subtype of lung cancer is non-
small cell lung cancer (NSCLC), which accounts 
for ~ 87%, of all lung cancers. 
Prognosis 
The five year survival rate (~15%) is very poor for 
lung cancer. In the case of advanced lung cancers, 
the 5-year survival rate is as low as 2%. Moreover, 
no effective screening strategy is available. 
Cytogenetics 
Cytogenetic abnormalities to chromosomes 3p, 5q, 
13q, and 17p are particularly common in small-cell 
lung carcinoma (Salgia and Skarin, 1998). 
Oncogenesis 
TGFBR2 is regarded as an important tumor 
suppressor that is altered in lung cancers. 
Microdeletions in the TGFBR2 gene are reported in 
non-small cell lung carcinoma (Wang et al., 2007). 
Further, studies showed decreased expression of 
TGFBR2, which is associated with the 
histopathological grading of NSCLCs (Xu et al., 
2007).  
Furthermore, reduced TGFBR2 expression in 
human NSCLC was found to be associated with 
smoking, reduced differentiation, increased tumor 
stage, increased nodal metastasis, and most 
importantly, reduced survival (Malkoski et al., 
2012). These results suggest that loss of this tumor 
suppressor is an important event in lung 
tumorigenesis. 
Breast cancer 
Disease 
Breast cancer is the second leading cancer in terms 
of incidence and is at fifth position with regards to 
cancer-associated mortality.  
The important sub-types of breast cancer are ductal 
carcinoma in situ (DCIS), lobular carcinoma in situ 
TGFBR2 (Transforming Growth Factor, Beta Receptor II (70/80kDa)) Sivadas VP, Kannan S 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(10) 740 
(LCIS), and invasive or infiltrating ductal 
carcinoma (IDC). 
Prognosis 
There is a good five year survival rate (>80%) for 
breast cancer. This scenario is primarily due to 
world-wide awareness programmes and 
improvement of early screening strategies. 
Cytogenetics 
The most consistent chromosomal regions that 
show gain are on 1q, 20q and 8q, while the most 
common regions of loss are on 3p and 6q.  
These chromosomal changes were more frequently 
found in high grade ductal breast carcinomas with 
overexpression of c-erbB-2 oncoprotein (Malamou-
Mitsi et al., 1999). Notably, gain of 3q is reported 
to be a stronger predictor of recurrence than grade, 
mitotic activity index (MAI) and other features in 
invasive breast cancers (Janssen et al., 2003). 
Oncogenesis 
The TGFβ signaling shows a dual role in breast 
cancers. Even though it is tumor suppressor 
initially, this signaling cascade can trigger lung 
metastasis of advanced breast cancers by inducing 
angiopoietin-like 4 (Padua et al., 2008).  
However, mutations in the kinase domain of 
TGFBR2 are reported in recurrent breast cancers. 
Since no mutations were observed in the primary 
tumors, TGFBR2 mutations might have a role in 
breast cancer recurrence (Lucke et al., 2001). 
Furthermore, TGFBR2 positivity is an independent 
prognostic factor for good disease-free survival and 
overall survival in human epidermal growth factor 
receptor-2 (HER2)-negative patients (Paiva et al., 
2010). 
Colorectal cancers 
Disease 
Colon and rectal cancers account for around 9.4% 
of all cancer cases.  
These cancers are at third position in terms of 
incidence and are at fourth position with regards to 
cancer-associated mortality. 
Prognosis 
There is a good five year survival rate (>80%) for 
stage 1 2 cases. However, the 5-year survival rate is 
only about 10% in stage IV colorectal cancers. 
Cytogenetics 
Colorectal cancers show frequent gains at 7p, 7q, 
8q, 16p, 20p and 20q, while losses are often at 18q. 
Interestingly, metastatic tumors show frequent 
gains at 8q and 20q and loss at 18q, suggesting 
these chromosomal aberrations are linked to the 
progression of colorectal cancer (Aragane et al., 
2001). DNA copy number loss at 18q12.2, 
involving BRUNOL4 that encodes a splicing factor, 
is an independent prognostic indicator for colon 
cancers (Poulogiannis et al., 2010). 
Oncogenesis 
Mutations in at least one member of the TGFβ 
signaling are demonstrated in ~50% colorectal 
cancers, there by confirming the tumor suppressor 
activity of this pathway in these cancers (Seoane, 
2006).  
Mutational inactivation of TGFBR2 in 
microsatellite unstable colon cancer is a frequent 
event. Further, in vivo experiments also confirmed 
the role of TGFBR2 inactivation in the 
establishment and progression of colorectal cancers 
(Biswas et al., 2004; Biswas et al., 2008). 
Stomach cancers 
Disease 
Gastric cancer is the fourth most common cancer 
worldwide, with ~988000 cases per year and 
second among mortality with ~737000 deaths per 
year. 
Prognosis 
The 5-year survival rate of gastric cancer is poor. 
Even in developed countries like USA, the five-
year survival is only 24%.  
This is due to the lack of early screening strategies. 
Cytogenetics 
The recurrent chromosomal abnormalities includes 
gains at 17q, 20q, 1p, 22q, 17p, 16p, 6p, 20p, 7p, 3q 
and 13q4 while losses at 18q, 3p, 5q and 9p are 
common (Wu et al., 2002).  
In gastric cancers gain of 1q32.3 has a correlation 
with lymph node status while loss of 18q22.1 was 
associated with poor survival (Weiss et al., 2004). 
Oncogenesis 
Frameshift mutations in the 10bp poly(A) repeat of 
TGFBR2 coding regions is frequent in gastric 
cancers with microsatellite instability (MSI).  
In contrast, gastric adenomas without MSI seldom 
exhibit TGFBR2 mutations.  
This suggest that TGFBR2 is the main target of 
genomic instability during the development of 
MSI(+) gastric cancers (Song et al., 2010). 
Prostate cancers 
Disease 
With ~0.9 million incident cases all over the world, 
prostate cancers are fifth common cancer in the 
world. Globally it is the sixth leading cause of 
cancer-related death in men, but it ranks second in 
the United States. 
Prognosis 
The survival rates of prostate cancer vary among 
region to region; overall the 5-year survival rate is 
>90%. 
Cytogenetics 
The most common aberrations are losses in 
chromosomes 5q, 6q, 8p, 10q, 13q, 16q, 17p, and 
18q and gains in 7p/q, 8q, 9p, and Xq.  
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Moreover, a chromosomal rearrangement in 21q is 
observed in over 50% of prostate cancers (Saramaki 
and Visakorpi, 2007). Further, recurrent 
breakpoints at 5q11, 8p11, and 10q22 were 
observed in prostate cancer cell lines, suggesting 
the importance of tumor suppressor/oncogenes in 
these regions (Pan et al., 2001). 
Oncogenesis 
The in vivo experiments have demonstrated that the 
conditional loss of TGFBR2 in prostatic stromal 
cells can trigger prostate cancer initiation, 
progression, and invasion (Bhowmick et al., 2004). 
Silencing of TGFBR2 through CpG methylation at 
site -140 is a common event in prostate cancers 
(Zhao et al., 2005). However, TGFβ signaling has 
been shown to induce vicious cycles of prostate 
cancer bone metastases by inducing parathyroid 
hormone-related protein (PTHrP) via Gli2 
(Kingsley et al., 2007). 
Liver cancers 
Disease 
Liver cancer is the third leading cause of cancer 
death after lung and stomach cancers. It causes 
~754000 deaths per year. The most common sub-
type of liver cancer is hepatocellular carcinoma, 
which accounts for approximately 75% of all 
primary liver cancers. 
Prognosis 
The 5-year survival rate of liver cancer is just above 
50%. This scenario is mainly due to the delay in 
diagnosis. Because of this delay, less than 40% of 
individuals with hepatocellular carcinoma are 
eligible for surgery and transplant. 
Cytogenetics 
Studies suggest deletions are frequent at 
chromosomal arms 1p, 4q, 6q, 8p, 9p, 11q, 12q and 
13q, whereas gains are common at 1q, 6p, 8q, 11q 
and 17q in samples positive for Hepatitis B and C 
virus (Tornillo et al., 2000). 
Oncogenesis 
In hepatic cancers, TGFBR2 downregulation is 
reported to be correlated with larger tumor size, 
poor differentiation, portal vein invasion, 
intrahepatic metastasis and shorter recurrence-free 
survival (Mamiya et al., 2010). Further, in vivo 
experiments revealed that TGFBR2 loss along with 
TGF-alpha over expression can cooperate in 
hepatocarcinogenesis (Baek et al., 2010). 
Oral cancers 
Disease 
With an estimated 263000 cases, cancers of the oral 
cavity account for 2% of the cancer burden 
worldwide.  
But they are the second most common cancer in 
males and the fourth most common cancer in 
females in Melanesia and South-Central Asia, 
accounting for 7% of the total cancers diagnosed in 
this region.  
The most common type of oral cancer is squamous 
cell carcinoma, which accounts for more than 90% 
of the cancers of the oral cavity. 
Prognosis 
The overall 5-year disease-specific survival rate for 
patients is approximately 50% throughout the world 
and is unchanged over past two decades. 
Cytogenetics 
Recurrent loss of chromosomes 9, 13, 18 and Y are 
reported in oral cancers whereas the most frequent 
chromosomal imbalances involves deletions at 
chromosome arms 3p, 7q, 8p, 11q, 17p.  
The chromosomal breakpoints in structural 
rearrangements frequently involve the centromeric 
regions of chromosomes 1, 3, 8, 14 and 15 as well 
as bands 1p22, 11q13 and 19p13 (Jin and Mertens, 
1993). 
Oncogenesis 
TGFBR2 mutations are frequent in oral cancers, 
kinase domain mutations being common.  
The loss of TGFBR2 expression in the tumor is 
associated with significantly reduced overall 
survival among oral cancer patients (Sivadas et al., 
2013). Further, metastatic oral cancers show 
significantly lower TGFBR2 expression as 
compared to primary tumour, indicating its anti-
metastatic activity in oral cancers (Paterson et al., 
2001). 
Pancreatic cancer 
Disease 
Even though pancreatic cancer is at 13th position, 
contributing only 2% of cancer incidence, it is at 
8tth position in terms of mortality and causes 4% of 
cancer associated deaths. The most common form is 
pancreatic ductal adenocarcinoma. 
Prognosis 
Pancreatic cancer shows an extremely poor 
prognosis. The 5-year relative survival rate is only 
6%. 
Cytogenetics 
The chromosomal region 18q21 that bears SMAD4 
gene is homozygously deleted in 30% to 37% 
pancreatic ductal adenocarcinomas. Other important 
alterations involve genomic gains of 3q, 8q, 11q, 
17q, and frequent loss of chromosome 17p, 6q, and 
8p (Hahn et al., 1996; Griffin et al., 2007). 
Oncogenesis 
Even though mutations in TGFBR2 occur at lower 
rate, the downstream molecule SMAD4 mutation 
rates are as high as 50% in pancreatic cancers 
(Venkatasubbarao et al., 1998; Cowgill and 
Muscarella, 2003). This signifies the importance of 
TGFβ-signaling in preventing pancreatic 
tumorigenesis. 
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Cervical cancers 
Disease 
The high-risk Human papillomavirus types 16, 18, 
31 and 45 are the cause of ~90% of the cervical 
cancer globally.  
These cancers are at 7th and 8th position in terms of 
global cancer incidence and deaths respectively. 
Prognosis 
There is a better 5-year survival rate for cervical 
cancers. The 5-year survival rate for the early stages 
of cervical cancer is ~92% while the overall 5-year 
survival rate is about 72%. 
Cytogenetics 
Studies have reported abnormalities of chromosome 
1 in up to 95% of cervical cancer samples. The 
main alterations included are the deletions of 
chromosome 1 at bands q32, p34, q42, p32, and 
p22.  
Further, abnormality of chromosome 4 occurs in 
92% cases (Sreekantaiah et al., 1988, Sherwood et 
al., 2000). 
Oncogenesis 
Though TGFBR2 mutations happen at lower rate in 
cervical cancers (Chen et al., 1999), in vivo 
experiments provided evidence that estrogen and 
HPV E7 proteins cooperate to silence TGFBR2 
expression during the induction and progression of 
cervical neoplasms (Diaz-Chavez et al., 2008). 
Leukemias 
Disease 
The haematological neoplasms can be broadly 
classified into four sub-types: Acute lymphoblastic 
leukemia (ALL), Chronic lymphocytic leukemia 
(CLL), Acute myelogenous leukemia (AML) and 
Chronic myelogenous leukemia (CML). 
Prognosis 
Prognosis varies from subtype to subtype. 
Cytogenetics 
The well-known chromosomal aberration in CML 
is a reciprocal translocation between chromosome 9 
and 22 designated as t(9;22)(q34;q11). This 
translocation generates the oncogenic Bcr-Abl 
fusion protein. Other important translocations 
involves t(4;11); t(11;14); and t(1;3). 
Oncogenesis 
Mutations in TGFBR2 associated with 
microsatellite instability were observed in 20% of 
cell lines derived from hematologic malignancies. 
Though alterations of the microsatellite regions in 
the TGFBR2 are not common in CML, but 
TGFBR2 downregulation was evident in CML cells 
as compared with the hematopoietic cells of normal 
donors.  
Furthermore, decreased TGFBR2 expression was 
also observed in the other haematological 
neoplasms (Rooke et al., 1999; Kim and Letterio, 
2003). 
Ovarian cancers 
Disease 
Majority of ovarian cancers arise in the epithelial 
surface of the ovary. They comprise ~2% of global 
cancer incidence and cancer-associated deaths. 
Prognosis 
Because more than 60% of ovarian cancers are 
diagnosed at a later stage, ovarian cancer has a 
relatively poor 5-year survival rate of ~47%. 
Cytogenetics 
The deletion of chromosome 3p region carrying 
TGFBR2 is a frequent event in ovarian cancers 
(Lounis et al., 1998).  
Further, abnormalities of chromosomes 1, 3, 6, and 
11 were found in metastatic effusions of ovarian 
cancer (Ioakim-Liossi et al., 1999).  
The breakpoints in regions 1p3 and 11p1 are 
important early events in ovarian cancers. 
Particularly, the ovarian cancers with breakpoints at 
1p1, 3p1 and 11p1 present poor prognosis (Simon 
et al., 2000). 
Oncogenesis 
Kinase domain mutations of TGFBR2 in up to 25% 
of ovarian cancers are reported.  
Added, loss of TGFBR2 expression was found in 
>40% of samples (Lynch et al., 2004).  
Epigenetic silencing of TGFBR2 through promoter 
methylation could be the reason for the loss of 
TGFBR2 expression, which is a common event in 
ovarian cancers (Matsumura et al., 2011). 
Renal carcinomas 
Disease 
Kidney cancers are generally originated in the 
lining of the proximal convoluted tubule. Renal cell 
carcinoma (RCC) is the most common type of 
kidney cancer, causing for 80% of cases. 
Prognosis 
Even though the five year survival rate among stage 
I patients is around 90%, while the 5-year survival 
rate is less than 10% for patients presenting with 
stage IV disease. 
Cytogenetics 
The deletion of the chromosome 3p region is the 
hallmark of nonpapillary/clear cell RCC (Siebert et 
al. 1998). 
Oncogenesis 
The downregulation of TGFBR3 and TGFBR2 are 
the important events during renal carcinogenesis  
and acquisition of metastatic phenotype 
respectively (Copland et al., 2003). The reason for 
the loss of TGFBR2 expression could be due to 
promoter hypermethylation (Zhang et al., 2005). 
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Glioblastoma multiforme 
Disease 
Glioblastoma is the most aggressive malignant 
primary brain tumor in humans, involving glial 
cells and account for more than 50% of all brain 
tumor cases. 
Prognosis 
The survival rates are very poor, most of the 
patients die within a period of 1-2 years. 
Cytogenetics 
Loss of heterozygosity (LOH) at 10q involving 
PTEN is the most common genetic alteration shown 
by both primary as well as secondary glioblastomas 
(Ohgaki et al., 2004). 
Oncogenesis 
p53 mutations are the most common event in 
glioblastomas. More than 30% of the primary and 
65% of the secondary glioblastomas show p53 
mutations (Ohgaki et al., 2004). Mutations in the 10 
bp poly(A) tract of TGFBR2 are very common 
(71%) in gliomas with genomic instability. 
However, TGFBR2 mutation rates are less (3%) in 
microsatellite stable gliomas (Izumoto et al., 1997). 
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